Cabio Biotech (Wuhan) , Ltd. Receivables

Cabio Biotech (Wuhan) , Ltd. (688089.SS) currently reports a receivables of $190M as of June 2026. That compares with $290M in the prior-year period — down 35.8% year over year. Use the charts on this page to explore Cabio Biotech (Wuhan) , Ltd.'s receivables history and peer comparisons.

Cabio Biotech (Wuhan) , Ltd.'s receivables decreased from $290M to $190M — a 35.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cabio Biotech (Wuhan) , Ltd. reported $190M in receivables as of June 2026. That compares with $290M in the prior-year period — down 35.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $190M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cabio Biotech (Wuhan) , Ltd., and consider following 688089.SS for alerts when major investors trade the stock.

Cabio Biotech (Wuhan) , Ltd. is classified in the Healthcare sector. On receivables, it currently shows $190M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 688089.SS with unrelated industries.